Neurology English Podcast

What you will learnThis conversation practices manual muscle testing using simple and clear English commands for neurological examination.Key wordsNeck flexors, Neck extensors, Deltoid, Biceps brachii, Triceps brachii, Wrist extensors, Wrist flexors, Pinch, Abductor pollicis brevis, First dorsal interosseous, Abductor digiti minimi, Flexor digitorum profundus, Iliopsoas, Rectus femoris, Hamstrings, Tibialis anterior, GastrocnemiusSourceClinical neurological examination (standard practice)NoteThis conversation is for educational purposes only.

What you will learnThis conversation introduces a step-by-step cranial nerve examination and helps you practice simple and practical English commands used in neurological exams.Key wordsOlfactory nerve. Optic nerve. Oculomotor nerve. Trochlear nerve. Trigeminal nerve. Abducens nerve. Facial nerve. Vestibulocochlear nerve. Glossopharyngeal nerve. Vagus nerve. Accessory nerve. Hypoglossal nerve.SourceClinical neurological examination (standard clinical practice).NoteThis conversation is for educational purposes only.

What you will learnThis episode reviews a multicenter retrospective study on cancer-associated stroke and explains why post-treatment plasma D-dimer levels, rather than pre-treatment levels, are independently associated with poor short-term outcomes and mortality. Key wordsCancer-associated stroke.Hypercoagulability.Recurrent.Cumulative.Mortality rate.Adjusted odds ratio.Anticoagulation therapy. SourcePost-Treatment Plasma D-Dimer Levels Are Associated With Short-Term Outcomes in Patients With Cancer-Associated Stroke.Front. Neurol.2022;13:868137.DOI:10.3389/fneur.2022.868137 NoteThis episode isfor educational purposes only. This is a summary and commentary, not theoriginal article. Episode 7, Stroke 1.

What you will learnThis episode reviews a multicentre retrospective study of corticosteroidtreatment in CIDP and explains that daily prednisolone, pulsed dexamethasone,and pulsed intravenous methylprednisolone showed broadly similar efficacy andsafety outcomes. Key wordsPulsed dexamethasone.Pulsed intravenous methylprednisolone.Remission rates.Cumulative steroid dose.Responder.Sourcevan Lieverloo GGA, Peric S, Doneddu PE, et al. Corticosteroids in chronicinflammatory demyelinating polyneuropathy: A retrospective, multicentre study,comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, andpulsed intravenous methylprednisolone. J Neurol. 2018;265:2052–2059. DOI:10.1007/s00415-018-8948-y. NoteThis episode is for educational purposes only. This is a summary andcommentary, not the original article.Episode 6, CIDP 3.

What you will learnThis episode reviews a multicentre UK study on very high dose immunoglobulin treatment in CIDP and explains why dose escalation may not always be the best option in patients with a poor response.  Key wordsPre-treatment disability.Maximal improvement.Thromboembolic complications.Suboptimal response.dose escalation. SourceVery High Dose Immunoglobulin Treatment for Chronic Inflammatory DemyelinatingPolyneuropathy: A Multicentre UK Study.Eur J Neurol. 2025;32(11):e70429.DOI: 10.1111/ene.70429. NoteThis episode is for educational purposes only. This is a summary and commentary, not the original article.Episode 5, CIDP 2.

What you will learnThis episode reviews a multicenter study on chronic inflammatory demyelinating polyradiculoneuropathy, or CIDP, and explains how early treatment may be a key modifiable factor in reducing long-term disability.Key wordsdeterminants, therapeutic factors, long-term disability, univariate and multivariate linear regression analyses, modifiable factorSourceDeterminants of long-term disability in chronic inflammatory demyelinating polyradiculoneuropathy: A multicenter Korea/UK study of 144 patients.Eur J Neurol. 2025;32(1):e16575.DOI: 10.1111/ene.16575NoteThis episode is for educational purposes only. This is a summary and commentary, not the original article.Episode 4, CIDP 1

What you will learnA short review of a serious case report involving lecanemab, t-PA, and multiple cerebral hemorrhages after acute ischemic stroke.Key wordscerebral hemorrhage, t-PA, homozygous, gaze preference, administer, intraparenchymal, cerebral amyloid angiopathySourceMultiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke.N Engl J Med. 2023;388:478-479.DOI: 10.1056/NEJMc2215148NoteThis episode is for educational purposes only. This is a summary and commentary, not the original article.Episode 3, dementia 3

What you will learnA short review of the TRAILBLAZER-ALZ 2 trial and how donanemab showed clinical benefit in early symptomatic Alzheimer’s disease.Key wordsearly symptomatic Alzheimer’s diseaseiADRSleast-squares mean changeCDR-SBamyloid plaqueARIAShort summaryThis episode reviews the TRAILBLAZER-ALZ 2 trial, published in JAMA in 2023. Donanemab slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease. Unlike Clarity AD, the pivotal trial of lecanemab, this study incorporated tau pathology into the trial design. The results supported the clinical benefit of anti-amyloid therapy, while adverse events such as amyloid-related imaging abnormalities remained important.SourceMintun MA, Lo AC, Duggan Evans C, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023.DOI: 10.1001/jama.2023.13239NoteThis episode is for educational purposes only. This is a summary and commentary, not the original article.Episode 2. Dementia 2

What you will learnA short review of a key paper in neurology, explained in simple English.Key wordsmonoclonal antibodyprotofibrilcognitive declineCDR-SBADAS-Cog14adjusted mean changeadverse eventsShort summaryLecanemab slowed cognitive and functional decline in early Alzheimer’s disease over 18 months. Clinical outcomes such as CDR-SB and ADAS-Cog14 also favored lecanemab, although adverse events remained important.Sourcevan Dyck CH, et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med. 2023.DOI: 10.1056/NEJMoa2212948NoteThis episode is for educational purposes only. This is a summary and commentary, not the original article.Episode 1, Dementia 1